About RED QUEEN THERAPEUTICS INC.
Red Queen Therapeutics is a clinical-stage company developing antiviral therapies based on a novel stapled lipopeptide platform technology to combat a broad range of virus-borne illnesses. Their approach focuses on early intervention by blocking virus-cell fusion, offering potential benefits for immunocompromised patients and reducing transmission.
Development of stapled lipopeptide fusion inhibitors to block virus-cell fusionDesign of antiviral therapies that prevent viral entry and accelerate viral clearanceFormulation of therapies as nasal spray, inhaler, or injection for self-administrationRapid customization of the platform against a broad range of virusesClinical-stage development of multiple programs targeting SARS-CoV-2, RSV, influenza, and herpes
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| RED QUEEN THERAPEUTICS, INC - AOI#25(FASTX) R&D FOR RAPID RESPONSE PLATFORM FOR THE DEVELOPMENT OF A PAN-INFLU | Department of Health and Human Services | $267K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to RED QUEEN THERAPEUTICS INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.